Medtronic has announced the 510(k) clearance and launch of the Shilla growth guidance system. The system is designed for treatment of skeletally immature paediatric patients less than 10 years of age diagnosed with severe, progressive, life-threatening, early-onset spinal deformities.
The Shilla growth guidance system is a new growth-sparing technology that allows correction of the deformity while maintaining the corrections over time, minimising the need for periodic lengthening procedures. This is different than current operative treatments, which are distraction based systems that require lengthening every six to nine months.
“Early onset scoliosis is extremely difficult to treat. The current gold standard technique to manage scoliosis long-term is to fuse the spine, but in children who are still growing this can have serious complications,” explains Shilla growth guidance system inventor Richard McCarthy, an orthopaedic surgeon and faculty member at the University of Arkansas for Medical Sciences/Arkansas Children’s Hospital. “Until now we were only able to offer operations which use implants to stabilise the curve in the spine, but these frequently mean twice-yearly surgeries as a child grows. The clearance of the Shilla growth guidance system marks the first time we can offer effective management of the curvature of the spine while still harnessing the child’s natural growth.”
The Shilla growth guidance system utilises a unique non-locking set screw at the proximal and distal portions of the construct’s rods. This specific feature allows the rod to slide through the screw heads as the child’s spine grows, while still providing correction of the spinal deformity.
“This clearance advances care for children with early-onset spinal deformities, and for their families and caregivers,” says Doug King, vice-president, president of Medtronic Spinal. “We want to thank our surgeon partners and the FDA for helping us bring the Shilla growth guidance system to an important patient population as we seek to address universal healthcare needs related to outcomes, costs and patient access.”
Since receiving CE mark approval in 2012, the Shilla growth guidance system has been used in 17 countries, on three continents.